
Erasca Executives Face Securities Lawsuit Over Misleading Trial Data
Investors have until August 10, 2026, to seek lead plaintiff status in a class-action lawsuit against Erasca, Inc. The litigation targets CEO Jonathan Lim and CFO David Chacko, accusing the executives of certifying false information regarding the company's ERAS-0015 drug trials while raising $258.8 million from the market.

























